Pharmaceutical - Victoza, Metabolics

Filter

Current filters:

VictozaMetabolics

Popular Filters

Novo Nordisk aims to expand its already leading position in diabetes care

Novo Nordisk aims to expand its already leading position in diabetes care

03-12-2013

Denmark-based global insulin giant Novo Nordisk this morning set out its ambition to further expand its…

DiabetesHematologyliraglutideMetabolicsNovo NordiskOG217SCPharmaceuticalsemaglutideVictoza

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

20-11-2013

Due to the launches of several novel drugs during the next decade, the obesity therapeutics market will…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNovo NordiskPharmaceuticalVictoza

Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial

24-05-2013

Danish insulin giant Novo Nordisk (NOV: N) has released headline results from a 56-week double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

New study shows Novo Nordisk's Victoza achieves 6% weight loss in type 2 diabetes patients

18-03-2013

Danish insulin giant Novo Nordisk (NOVN: N) has released headline results from a 56-week, double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

Obesity drug market set to grow to $2.6 billion by 2020, says DR report

27-09-2011

The obesity drug market will increase more than six-fold over the next decade, increasing from $420 million…

Arena PharmaceuticalsContraveLorqessMarkets & MarketingMetabolicsNovo NordiskOrexigen TherapeuticsPharmaceuticalQnexaVictozaVivus

Back to top